Business News • PR NewsWire • Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival

Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival

Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival

TARRYTOWN, N.Y. and PARIS, March 15, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy Trial enrolled patients with advanced cervical cancer...

View More : https://www.prnewswire.com:443/news-releases/phase-3-trial-of-libtayo-cemiplimab-monotherapy-in-advanced-cervical-cancer...

Releted News by prnewswire

Multimedia-Kunstwerke von acht Künstlergruppen werden ab dem 27. Februar an den Flughäfen Haneda und Narita ausgestellt

LTI encabeza la lista IT Services Challenger 2021 de Everest Group

Sectra's nine-month interim report 2020/2021: Increased order bookings and the industry's most satisfied customers for the eighth consecutive year

Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival

Scienjoy Launches Licensing and E-Commerce Partnership with the Great Wall of China

Nippon Express Launches Halal-certified Domestic Air Cargo Transport Service